TissueScan, Prostate Cancer cDNA Array III from OriGene Technologies

Product Specs
ItemTissueScan, Prostate Cancer cDNA Array III
CompanyOriGene Technologies
Price $1,060.00Supplier Page View Company Product Page
Catalog NumberHPRT103
Quantity2 Panels
TypeTissueScan
TissueProstate
DiseaseProstate Cancer

Add to Compare List

OriGene Technologies

9620 Medical Center Drive # 200

Rockville, Maryland 20850

United States

Phone: 1-888-267-4436 (U.S. only) / 301-340-3188
301-340-9254

Company Profile

Website: http://www.origene.com

(1) Novel roles for HMGA2 isoforms in regulating oxidative stress and sensitizing to RSL3-Induced ferroptosis in prostate cancer cellsHeliyonApril 1, 2023Campbell T, Hawsawi O, Henderson V, Dike P, Hwang BJ, Liadi Y, White EZ, Zou J, Wang G, Zhang Q, et al.safety. Prostate normal and cancer tissue cDNA array (TissueScan, Prostate Cancer cDNA Array III- CAT#: HPRT103) was purchased from OriGene (Rockville, MD). All samples were collected under IRB approved protocols.

(2) Role of opiorphin genes in prostate cancer growth and progressionFuture oncology (London, England)June 1, 2021Mukherjee A, Park A, Wang L, Davies KP.of PROL1 in PrCa, a cDNA array from normal and cancerous prostate tissue was purchased from OriGene (HPRT103; TissueScan™ cDNA Arrays; Origene, MD, USA). This array has 48 cDNA samples covering nine normal, 18

(3) The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotypePeerJFebruary 1, 2021Patrick B. Thomas et al.expression of GHSROS in prostate cancer TissueScan Prostate Cancer Tissue qPCR panels (HPRT101, HPRT102, and HPRT103) were obtained from OriGene. The cDNA panels contained of a total of 24 normal prostate-derived samples,

(4) ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signalingOncogeneFebruary 1, 2019Pai VC, Hsu CC, Chan TS, Liao WY, Chuu CP, Chen WY, Li CR, Lin CY, Huang SP, Chen LT, et al.

(5) Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5Cancer scienceNovember 1, 2018Lin CY, Jan YJ, Kuo LK, Wang BJ, Huo C, Jiang SS, Chen SC, Kuo YY, Chang CR, Chuu CP.

(6) TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasisThe Journal of clinical investigationJuly 2, 2018Singh R, Karri D, Shen H, Shao J, Dasgupta S, Huang S, Edwards DP, Ittmann MM, O'Malley BW, Yi P.

(7) Role of WNT5A receptors FZD5 and RYK in prostate cancer cellsOncotargetJune 5, 2018Thiele S, Zimmer A, Göbel A, Rachner TD, Rother S, Fuessel S, Froehner M, Wirth MP, Muders MH, Baretton GB, et al.

(8) Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasisOncogeneAugust 10, 2017Ko CJ, Lan SW, Lu YC, Cheng TS, Lai PF, Tsai CH, Hsu TW, Lin HY, Shyu HY, Wu SR, et al.

(9) Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate CancerInternational journal of molecular sciencesNovember 29, 2016Lin VC, Lu TL, Yin HL, Yang SF, Lee YC, Liu CC, Huang CY, Yu CC, Chang TY, Huang SP, et al.

(10) Recurrent cis-SAGe chimeric RNA, D2HGDH-GAL3ST2, in prostate cancerCancer lettersSeptember 28, 2016Qin F, Song Z, Chang M, Song Y, Frierson H, Li H.clinical implications, we purchased a TissueScan prostate cancer and normal prostate cDNA array set (HPRT103) from OriGene. All of the cDNAs were quality controlled, and had similar levels of B-actin. RT-PCR showed

(11) ZFP91: A Noncanonical NF-κB Signaling Pathway Regulator with Oncogenic Properties Is Overexpressed in Prostate CancerBioMed research internationalJanuary 1, 2016Paschke L, Jopek K, Szyszka M, Tyczewska M, Ziolkowska A, Rucinski M, Malendowicz LK.extracted using a DNA 2.1. Prostate Cancer cDNA Samples. Prostate Cancer cDNA Array III (Origene, HPRT103) was utilized providing samples from 48 prostate cancer patients. Description of every sample includes

(12) Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axisScientific reportsNovember 13, 2015Hu X, Garcia C, Fazli L, Gleave M, Vitek MP, Jansen M, Christensen D, Mulholland DJ.

(13) WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivoJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchMarch 1, 2015Thiele S, Göbel A, Rachner TD, Fuessel S, Froehner M, Muders MH, Baretton GB, Bernhardt R, Jakob F, Glüer CC, et al.

Be the First to Write a Review!